Regulatory Risk and Business Development: Type 2 Diabetes Falls Out of Favor

It's a buyer's market for type 2 diabetes drugs, and you can thank FDA for that. At least, that is the sentiment of business development executives from Big Pharma. Transaction data in 2008 back up that view.